Squarepoint
ABVC icon

Squarepoint’s ABVC BioPharma ABVC Stock Holding History

Squarepoint’s Portfolio ABVC Stock Details ABVC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.2K Buy
+10,547
New +$17.4K ﹤0.01% 4186
2021
Q4 		– Sell
-1,921
Closed -$44K – 3112
2021
Q3 		$44K Buy
+1,921
New +$54.4K ﹤0.01% 2781

Other funds holding ABVC

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Squarepoint's ABVC Position: Q1 2026 in Review

Squarepoint opened a new position in ABVC BioPharma (ABVC) in Q1 2026: 10,547 shares worth $10.2K. The stake represents ﹤0.01% of the portfolio and ranks #4186 among its holdings. This is a return to the name: Squarepoint previously reported a position in ABVC as recently as Q3 2021.

Squarepoint first reported a position in ABVC in Q3 2021 and has held it in 2 quarters since. The position peaked at $44K in Q3 2021. 13 funds tracked by Wall St. Rank hold ABVC as of Q1 2026.

  • Squarepoint held 10,547 shares of ABVC BioPharma worth $10.2K as of Q1 2026.
  • ABVC BioPharma was a new Squarepoint position in Q1 2026.
  • ABVC BioPharma made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #4186 holding.
  • Squarepoint first reported a position in ABVC BioPharma in Q3 2021 and has held it in 2 quarters since.
  • Squarepoint's ABVC BioPharma position peaked at $44K in Q3 2021.
  • 13 funds tracked by Wall St. Rank held ABVC BioPharma as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.